Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reaffirmed at Berenberg Bank

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by investment analysts at Berenberg Bank in a research report issued on Monday,Digital Look reports. They presently have a GBX 2,560 ($33.14) price target on the stock. Berenberg Bank’s price target indicates a potential upside of 23.67% from the stock’s previous close.

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th.

Hikma Pharmaceuticals Stock Performance

Shares of LON:HIK traded down GBX 34 ($0.44) on Monday, reaching GBX 2,070 ($26.80). 341,885 shares of the company’s stock were exchanged, compared to its average volume of 2,103,955. The business’s 50-day moving average is GBX 2,175.22 and its two-hundred day moving average is GBX 2,013.78. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,750 ($22.66) and a fifty-two week high of GBX 2,360 ($30.55). The firm has a market capitalization of £5.74 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 2.38 and a beta of 0.41.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.